Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04179 (
MnSOD
)
2,777
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Preconditioning with sublethal ischemia results in natural tolerance to ischemic stress, where multiple mediators of ischemic damage are simultaneously counteracted.
Tumor necrosis factor alpha
(
TNF-alpha
) has been implicated in development of ischemic tolerance. Using cellular models of ischemic tolerance, we have demonstrated that an effector of
TNF-alpha
-induced preconditioning is ceramide, a sphingolipid messenger in
TNF-alpha
signaling.
TNF-alpha
/ceramide-induced preconditioning protected cultured neurons against ischemic death and cultured astrocytes against proinflammatory effects of
TNF-alpha
.
TNF-alpha
activates a transcription factor NF-kappaB that binds promoters of multiple genes, thus ensuring pleiotropic effects of
TNF-alpha
. We describe here a mechanism that allows selective suppression of
TNF-alpha
/NF-kappaB-induced harmful genes in preconditioned cells while preserving cytoprotective responses. We demonstrate that in astrocytes activation of an adhesion molecule ICAM-1 by
TNF-alpha
is regulated through association of the phosphorylated p65 subunit of NF-kappaB with an adapter protein, p300, and that in preconditioned cells p65 remains unphosphorylated and ICAM-1 transcription is inhibited. However,
TNF-alpha
-activated transcription of a protective enzyme,
MnSOD
, does not depend on p300 and does not become inhibited in preconditioned cells. This new understanding of
TNF-alpha
-induced adaptation to ischemic stress and inflammation could suggest novel avenues for clinical intervention during ischemic and inflammatory diseases.
...
PMID:TNF-alpha-induced tolerance to ischemic injury involves differential control of NF-kappaB transactivation: the role of NF-kappaB association with p300 adaptor. 1182 12